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Sequential infection with different strains of human immunodeficiency virus type 1 (HIV-1) is a rarely
identified phenomenon with important implications for immunopathogenesis and vaccine development. Here,
we identify an individual whose good initial control of viremia was lost in association with reduced containment
of a superinfecting strain. Subject 2030 presented with acute symptoms of HIV-1 infection with high viremia
and an incomplete seroconversion as shown by Western blotting. A low set point of viremia (1,000 HIV-1
copies/ml) was initially established without drug therapy, but a new higher set point (40,000 HIV-1 copies/ml)
manifested about 5 months after infection. Drug susceptibility testing demonstrated a multidrug-resistant
virus initially but a fully sensitive virus after 5 months, and an analysis of pol genotypes showed that these were
two phylogenetically distinct strains of virus (strains A and B). Replication capacity assays suggested that the
outgrowth of strain B was not due to higher fitness conferred by pol, and env sequences indicated that the two
strains had the same R5 coreceptor phenotype. Delineation of CD8-T-lymphocyte responses against HIV-1
showed a striking pattern of decay of the initial cellular immune responses after superinfection, followed by
some adaptation of targeting to new epitopes. An examination of targeted sequences suggested that differences
in the recognized epitopes contributed to the poor immune containment of strain B. In conclusion, the rapid
overgrowth of a superinfecting strain of HIV-1 of the same subtype raises major concerns for effective vaccine
development.
The global distribution of circulating recombinant forms of
human immunodeficiency virus type 1 (HIV-1) M group
strains and the high prevalence of intersubtype recombinants
in some areas where multiple subtypes are common (reviewed
in reference 35) demonstrate that dual infection with different
strains of HIV-1 occurs. However, specific examples of dual
infection have been documented clearly in only a few cases.
Most of these examples have been observations of chronically
infected patients with two different subtypes in countries where
more than one subtype is prevalent (4, 7, 30, 37, 38), and a few
examples of intrasubtype B dual infections have been de-
scribed (14, 40, 41, 51). Whether these dual infections occurred
as coinfections or superinfections is unknown, and the influ-
ence of cellular immunity on coexisting viruses has been largely
undefined.
A few cases of superinfection, usually involving superinfect-
ing strains that differ in antiretroviral drug susceptibility from
the initial variant, have been identified. One individual was
initially infected with a strain of HIV-1 belonging to clade
CRF01_AE and, after a series of therapy interruptions, be-
came superinfected with a B subtype strain (21). Another in-
dividual was initially infected with a drug-resistant strain but
became superinfected in the absence of therapy with a drug-
sensitive strain of the same subtype (23). One study explored
the possible role of cellular immune responses in an individual
who was undergoing structured treatment interruptions and
had achieved relatively stable control of viremia, subsequently
becoming superinfected with another B subtype strain and
suffering an acute rise in viremia (2). However, data regarding
the role of cellular immunity in superinfection in the absence
of drug therapy have been lacking.
We have studied a subject who was initially infected with a
multiply drug-resistant strain of HIV-1 subtype B. He con-
trolled the initial infection well in the absence of antiretroviral
therapy but became superinfected 4 months later with a sec-
ond, drug-sensitive strain and showed a marked rise in viremia.
Detailed genetic and immunological characterization showed
that cytotoxic T-lymphocyte (CTL) responses against the first
strain waned with outgrowth of the second strain. The failure
of immune containment of the second strain despite early
infection and an initially effective HIV-specific CTL response
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exemplifies a significant challenge to the development of ef-
fective vaccines.
MATERIALS AND METHODS
The subject. Subject 2030 was a 33-year-old homosexual Asian-American male
with no significant past medical history who presented after 10 days of an acute
illness. He reported multiple ongoing unprotected sexual exposures as a risk
factor for HIV-1 infection and was subsequently found to be seropositive. These
studies were conducted with appropriate subject consent and approved by the
Human Research Protections Program at the Harbor-UCLA Medical Center
Research and Education Institute, University of California, Los Angeles, Calif.
HLA typing. High resolution HLA typing was performed by Pel-Freez Bio-
logicals.
HIV-1 phenotyping. Antiretroviral susceptibility was determined by Phe-
noSense (ViroLogic, Inc.) as previously described (36). In this assay, a region
extending from p7gag to amino acid 300 in reverse transcriptase (RT) is RT-PCR
amplified from plasma viral RNA and inserted into the test vector. This con-
struct, after transfection into the target cells, is used in a single cycle assay in the
presence of drug for assaying drug susceptibility; similarly, in the absence of drug,
it is used for assaying endogenous replication capacity (9). In both assays, the
replication rate is compared to the replication rate of the control strain HIV-1
clone NL4-3.
HIV-1 genomic sequencing and phylogenetics. Sequencing of viral genomic
regions containing CTL epitopes was performed after RT-PCR amplification of
plasma viral RNA (extracted with Finnzyme one-step RT-PCR kit, MJ Research,
Waltham, Mass., or RNA isolation kit, QIAGEN, Valencia, Calif.). Primers to
sequence HIV-1 were those employed by Altfeld et al. (2) (except those for Env),
including 737-F (GCG ACT GGT GAG TAC GCC), 2095-R (TTC CCT AAA
AAA TTA GCC TG), 1232-F (ACC TAG AAC TTT AAA TGC ATG GG),
1754-R (CAA CAA GGT TTC TGT CAT CC), 1816-F (TAG AAG ACA TGA
TGA CAG CAT G), 3018-R (GGT GAT CCT TTC CAT CC), and 2422-R
(TCT TAC TTT GAT AAA ACC TCC) (Gag); 5040-F (ATG GAA AAC AGA
TGG CAG G), 6455-R (GGG TCT GTG GGT ACA CA), and 5579-R (GGT
CTT CTG GGG CTT GTT CC) (Vif); 5692-F (TAT CTA TGA AAC TTA TGG
GGA TAC) and 6229-R (CTT TCA TTG CCA CTG TCT TC) (Tat/Rev);
7361-F (TTA ATT GTG GAG GAG AAT TTT T), 9403-R (ACT CCG GAT
GCA GCT CTC GGG C), 8804-F (ATG GGT GGC AAG TGG TC), and
9239-R (ACT GGT ACT AGC TTG AAG CAC C) (Nef); V3-F out (CAA AGG
TAT CCT TTG AGC CAA T), V3-B out (ATT ACA GTA GAA AAA TTC
CCC T), V3-B in (GCG TTA AAG CTT CTG GGT CCC CTC CTG AG), and
V3-F in (GAA CAG GAC CAG GAT CCA ATG TCA GCA CAG TAC AAT)
(Env). DNA fragments were then gel purified (gel purification kit; QIAGEN)
and cloned into the TOPO TA vector (Invitrogen Corp., Carlsbad, Calif.). For
each fragment, a minimum of three individual clones were sequenced to obtain
consensus sequences for each time point. PCR products were sequenced with
Prism Dye terminator kits (ABI, Foster City, Calif.) on an ABI 3100 Genetic
Analyzer. Sequences were compiled, aligned, and edited by using Sequencher 4.0
(Genecodes, Ann Arbor, Mich.) and BioEdit (17), and phylogenetic analysis was
performed by using MEGA2 (26). Neighbor-joining phylogenetic trees for the
reverse transcriptase and protease coding region were obtained from a matrix of
synonymous nucleotide distances. This method is most appropriate in regions
where there is strong selection on nonsynonymous changes, which otherwise can
lead to incorrect trees (demonstrated at http://www.hiv.lanl.gov/content/hiv-db
/CONTAM/contam_conserved.html).
ELISPOT analysis of HIV-1-specific CD8-T-cell responses. Nonspecifically
expanded CD8 T cells were screened to define HIV-1-specific responses by
using a standard gamma interferon enzyme-linked immunospot (ELISPOT)
assay as previously described (49). Briefly, cryopreserved peripheral blood mono-
nuclear cells from the indicated times were polyclonally expanded to yield CD3/
CD8 lymphocytes by using a CD3:CD4-bispecific antibody (50) and evaluated
for reactivity against overlapping HIV-1 subtype B 15-mer peptide sets (most of
which are based on a consensus sequence) obtained from the NIH AIDS Re-
search and Reference Reagent Repository (ARRRR; catalogue numbers 6869,
6208, 6451, 5189, 5138, 6445, 6446, 6447, and 6444). Initial screening was per-
formed on pools of 16 or fewer peptides, followed by analysis of 4-by-4 matrix
pools and confirmation using individual peptides. This method is reported to
result in a small but quantitatively consistent bias in the expansion of antigen-
specific CD8 T lymphocytes (3, 20), in agreement with our own experience
comparing ELISPOT responses with fresh and expanded CD8 peripheral blood
mononuclear cells (r2  0.58 for comparisons within nine chronically infected
persons; data not shown).
RESULTS
Clinical presentation and course of subject 2030. Subject
2030 presented with an acute syndrome of fever, rash, myalgia,
cervical lymphadenopathy, oral ulcers, and headache of 10
days duration. Upon presentation, he had a positive serum
ELISA for HIV-1 antibodies, a borderline Western blot for
HIV-1 (bands for gp160 and p24 only), a peripheral blood
CD4-T-lymphocyte count of 396 cells/l, and viremia of ap-
proximately 300,000 HIV-1 copies of HIV RNA/ml of plasma.
Subsequently, the viremia decreased to an initial set point of
approximately 1,000 copies/ml, and the CD4-T-lymphocyte
count rose to over 600 cells/l (Fig. 1). However, after this
period of relative stability following acute infection, plasma
viremia rose sharply to a new plateau of approximately 30,000
to 40,000 copies/ml at 5 months after presentation, with a
concomitant decline in the CD4-T-lymphocyte count to
about 450 cells/l. Subject 2030 reported ongoing high-risk
sexual exposures, raising the possibility that this acute change
in set point could be due to HIV-1 superinfection.
Dramatic shift in HIV-1 phenotype and genotype indicating
infection with two distinct strains. Phenotypic testing revealed
that the initial infecting virus was resistant to multiple drugs
(Fig. 2). The 50% inhibitory concentration of drug (IC50) of
the baseline sample was 50-fold higher than the wild-type con-
trol HIV-1NL4-3 for zidovudine, approximately 160-fold higher
for delavirdine, and 13-fold higher for nelfinavir. The pol ge-
notype revealed multiple resistance-associated mutations in
both protease (PR) and RT: V77I and L90 M in PR; and
M41L, K103N, Y181C, T215F, and an insertion of two serine
amino acids at position 69.
When viremia rose at month 5 (Fig. 1), this initially drug-
resistant phenotype abruptly shifted to a phenotype that was
susceptible to all tested drugs (Fig. 2). Genotyping at this point
revealed none of the prior drug resistance mutations and
showed distinct variations at polymorphic sites other than
those associated with drug resistance. A phylogenetic analysis
of protease and reverse transcriptase for this subject, and for
control subjects in the same area with acute HIV-1 infection
within the year, confirmed that the initial virus strain (A) and
FIG. 1. Subject 2030 plasma HIV-1 and CD4-T-lymphocyte
counts over the first 10 months of infection. Viremia (RNA genomes
per ml of plasma; squares) and absolute CD4-T-lymphocyte concen-
trations (cells/l of blood; diamonds) for subject 2030 are plotted.
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the subsequent strain (B) were phylogenetically distinct (Fig.
3). The genetic distance between strains A and B at synony-
mous sites within the sequenced gag-pol region was 15.42 
2.0%. This genetic distance was greater than that seen in 95%
of comparisons among local acute HIV-1 infections involving
subtype B (mean, 11.98%; maximum, 16.8%). The nef genes of
the strains also were clearly distinct, although not as divergent
as gag-pol. Within nef, nonsynonymous sites differed more, on
average, between the two than did synonymous sites (dN 
5.7% and dS  4.5%, as estimated by the modified Nei-Gojo-
bori method with Jukes-Cantor correction for multiple hits). In
the C2V3 region of env, however, there is no difference be-
tween dN and dS
43, and a single overall rate was estimated. On
the basis of 12 clonal sequences 409 bp in length from each of
the two strains (strain A, month 3; strain B, month 7), the
mean genetic distance was 19.2  0.039% (Tamura-Nei model
with -distributed rates;  value, 0.4). Overall, sequence data
from across the genome clearly demonstrated infection of this
individual with two distinct HIV-1 strains.
Recombination between strains A and B. Very little viral
sequence diversity accumulated in the first three months of
infection, with the exception of amino acid position 215 in RT.
At month 4, the consensus sequence contained a series of
mixtures at both synonymous and nonsynonymous positions,
clustered between amino acids 190 and 300 in RT. These
mixtures generally contained one nucleotide identical to the
consensus sequence from the first 3 months (strain A) and
another nucleotide corresponding to the subsequently distinct
consensus sequence at 6 months (strain B; Fig. 4). The most
parsimonious reconstruction of the month 4 pol genotype
therefore was a mixture of two distinct sequences, one from
strain A and a second recombinant of strains A and B. Only at
amino acid 215 in RT, where one of the parental alternatives
(T) was not detected, was this reconstruction ambiguous. This
was the first evidence of the presence of strain B in Subject
2030 and the only evidence of recombination between the two
infecting strains detected in this study.
Reduced replicative capacity of pol in strain A compared to
strain B. The phenotypes of the pol genes from the two strains
were compared also by using the ViroLogic replication capac-
ity assay (Fig. 5). This assay correlates significantly with in vitro
fitness and usually, in the context of drug resistance, with
plasma viremia (9). The assay compares the number of infec-
tive particles produced (in the absence of drug) by recombi-
nant viruses containing subject-derived gagp7-RT segments in
an NL4-3 backbone. Normalized to the average of subject-
derived viruses, the mean replicative capacity for strain A (i.e.,
before month 4) was 35% of wild-type subject-derived virus
isolates (range, 64 to 12%), while that for strain B (after month
4) was 8% (12 to 1.5%) of wild-type subject-derived virus
isolates. The generally lower value for strain B was consistent
with the observation of protease hypersusceptibility of this
strain (data not shown), which has been associated with low
replicative capacity (29). These data show that the in vivo
overgrowth of strain A by strain B was not a result of lower
intrinsic replicative ability of strain A associated with drug
resistance mutations in pol, raising the question of differential
immune containment of the two viruses.
Coreceptor usage of strains A and B. Because the corecep-
tor usage of HIV-1 determines the cells that can serve as
targets of infection and is associated with disease pathogenesis,
the usages of strains A and B were determined by sequencing
of the C2V3 region of Env. Clonal sequences obtained from
the plasma were assessed for amino acids at positions 11 and
25 of V3, because CXCR4 coreceptor usage is determined by
specific amino acid substitutions in the V3 region of env, no-
tably basic amino acid substitutions (16). Although the V3 loop
sequences of the strains were distinct (12 clonal sequences
each from the month 3 and month 12 time points, data not
shown), 12 of 12 clones from strain A (month 3) and 11 of 12
clones from strain B (month 12) had serine at position 11.
Similarly, 12 of 12 strain A and 11 of 12 strain B sequences had
an acidic residue at position 25 (glutamic acid in strain A and
aspartic acid in strain B). One strain B clone had asparagine at
position 11 and another had asparagine at position 25, but no
clone had negatively charged amino acids at both positions.
Thus, there was no significant difference between the two
strains with respect to predicted coreceptor usage, with both
strains being the R5 phenotype.
Evolution of CD8 cellular immune responses suggesting
differential recognition of the viruses. The initially low set
point of viremia followed by the subsequent sharp increase (in
the absence of antiretroviral therapy) suggested a change in
immune control over time. We therefore analyzed the HIV-1-
specific CD8-T-lymphocyte responses by gamma interferon
ELISPOT assays (Table 1). Recognition of epitopes in Gag,
Nef, and Vif was observed as early as 17 days after the onset of
symptoms of acute infection. These early responses generally
persisted during the subsequent 3 months, accompanied by
broadening to recognize additional epitopes in Gag and Tat.
However, after the fifth month, the early responses waned, and
new responses were noted in Nef and Rev by the ninth month.
Classifying CTL responses as those detected at the first time
point (“early responses”) or only afterwards (“late responses”)
demonstrated a clear pattern of evolution (Fig. 6), with the
magnitude of early responses declining consistently starting in
the third month and the magnitude of late responses rising
sharply starting in the fifth month. In the context of superin-
fection and overgrowth of strain A by strain B, these data
strongly suggest that the initial CTL responses were specific to
FIG. 2. Subject 2030 plasma virus phenotypic susceptibility to dela-
virdine, zidovudine, and nelfinavir over the first 12 months of infection.
Changes (n-fold) in the 50% inhibitory concentration (IC50) are plot-
ted for delavirdine (DLV; squares), and zidovudine (ZDV; diamonds)
using the y axis on the left and for nelfinavir (NFV; triangles) using the
y axis on the right.
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strain A and poorly recognized strain B; while there was adap-
tive retargeting of responses, this retargeting was inadequate
to contain strain B to the degree that the initial responses had
contained strain A.
Differences in strain A and strain B CTL epitopes. To ex-
amine whether sequence differences might account for differ-
ential immune control of the two viruses, regions targeted by
CTL were sequenced from strains A and B (Table 2). The in
vivo viral sequences corresponding to the recognized screening
peptides were compared in the context of the HLA type of the
subject (A*03, A*24, B*35, and B*40). Of responses that ex-
ceeded 100 spot-forming cells (SFC)/106 CD8 T lymphocytes,
the majority that waned after superinfection contained poten-
tially significant differences in strain B compared to strain A.
FIG. 3. Phylogeny of pol sequences for subject 2030 and other HIV-1 infected persons in the Los Angeles area. Serial pol sequences from
subject 2030 were compared to those of other HIV-1-infected persons presenting with acute infection in the Los Angeles area from 1998 to 2000.
Consensus sequences of PR and 315 codons of RT were used to construct a neighbor-joining tree on synonymous sites by using a modified
Nei-Gojobori model, rooted on HIV-1HXB2R (25). The percentage of bootstrap resamples (out of 1,000) in which a clade was identified are shown
when above 70%. Sequences from subject 2030 are distinguished by month (2030.M0 to 2030.M12) and identified as strain A and strain B.
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These differences included an insertion of four amino acids
flanking a predicted epitope (Table 2, row 4) and changes
within the TCR-binding region (Table 2, rows 6 and 8) or
HLA-binding motif (Table 2, row 9) of the predicted epitopes
in four of six examples. Two of these six examples (Table 2,
rows 1 and 2) showed no difference between the strains. How-
ever, it is clear that this waning of the initial responses was not
due to generalized immune deficiency, because a vigorous new
response against Rev was generated after superinfection (Ta-
ble 2, row 8). The recognized region of Rev contained two
amino acid differences in the TCR-binding region of the pre-
dicted epitope in strain A compared to strain B, and the
screening peptide was identical to strain B in this sequence.
Furthermore, the persistence of an early response recognizing
a predicted epitope that was identical in strains A and B (Table
2, row 5) indicated that the decay of the early responses was
selective. Overall, these findings are consistent with significant
epitope differences in the two viruses having a central role in
differential immune containment by CTL and persistence of
the CTL response.
DISCUSSION
Previous studies of the evolution of the HIV-1 quasispecies
within infected individuals led to the widespread belief that
superinfection is a rare event (5, 10–13, 18, 27, 28, 31, 33, 34,
39, 42–48). While dual infection was demonstrated to be pos-
sible (51), only recently have clear examples of superinfection
emerged (2, 21). These two cases demonstrated superinfection
in subjects who underwent structured treatment interruptions
with partial control of viremia, presumed to be immunologi-
cally mediated. Other recent studies, including a third case in
which coinfection or superinfection occurred in the absence of
therapy (23), suggest that it can occur in the setting of natural
infection without alteration of immunity by pharmacologic in-
tervention. The case described here extends these novel find-
ings and clearly documents superinfection after an initial in-
fection reaching a stable set point in the absence of
antiretroviral treatment as a confounding factor.
It is impossible to entirely exclude the possibility that a
superinfecting strain was present as an initial coinfection. In
the case of subject 2030, however, overgrowth by strain B
occurred rapidly and completely once it was detected, showing
that its overall growth advantage in vivo was great. If present
during acute infection, this overgrowth should have occurred
much earlier than 4 months after infection. This example is
striking because superinfection was clearly documented after a
stable viremia set point was established, in contrast to most
published reports. The subject had developed a broad and
stable CTL response to the first virus and reached an equilib-
rium of viremia, suggesting efficient immune suppression of
viral replication. Strain B, which was highly genetically distinct
from strain A, was detectable only at 4 months after primary
infection, but it rapidly overgrew strain A with a substantial
increase in viremia set point. A fitness assessment of the pol
genes showed a lower replication capacity for strain B than
strain A, suggesting that substantially greater intrinsic replica-
tive fitness due to differences in pol was not the mechanism of
this overgrowth. Although fitness differences due to genes
other than pol have not been excluded, the high level of vire-
mia during primary infection suggested that strain A was not
generally defective in replicative capacity. Furthermore, an
evaluation of coreceptor usage revealed that both strains were
predominately the R5 phenotype, making it unlikely that a
difference in tropism could account for differences in replica-
tion in vivo. This finding indicates that differential immune
containment of strain B versus strain A could be the key factor.
Consistent with the report on immune responses of a subject
who had superinfection after structured treatment interruption
(2), we found that our subject had developed a stable and
broadening repertoire of CTL responses against the initial
virus, which failed to prevent or contain infection with the
second virus. Sampling of epitope sequences revealed signifi-
cant differences between the viruses, suggesting that the mech-
anism of immune failure was nonrecognition of the second
FIG. 4. Recombinant RT sequence detected in month 4 sample. .,
same amino acid as in baseline sequence; *, difference from baseline at
synonymous nucleotide site in that codon; –, codon deletion; #A,
reconstructed month 4 sequence of strain A type; #R, reconstructed
month 4 sequence of recombinant type. The month 4 sequence showed
a series of ambiguity codes at sites towards the carboxy-terminal end of
the sequenced region, which when resolved always included the nucle-
otide observed with strain A. This result is most readily interpreted as
indicating that a recombinant sequence reached significant frequencies
at this time point. No recombinant sequence was observed at any other
time point.
FIG. 5. Replicative capacity of subject 2030 pol and plasma viremia
over time. Replication capacity (as determined by the PhenoSense
assay of pol) and plasma viremia are shown over the period of shift
from viremia with strain A (months 0 to 3) to that with strain B
(months 5 to 10). Squares, viremia (RNA genomes per ml of plasma);
diamonds, replicative capacity (RC; percentage of median wild-type
value).
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strain. Strikingly, the majority of CTL responses decayed rap-
idly after superinfection, similar to the observed loss of CTL
after epitope mutation and escape occurring in chronically
infected persons (19). Furthermore, while new CTL responses
were detected after superinfection, these were fewer and failed
to contain the second virus. This result could have been a
consequence of the divergent sequence of the superinfecting
strain or might imply a role for a mechanism, such as original
antigenic sin (22), limiting the adaptability of CTL responses
after initial infection.
The marked rise in viremia after superinfection is consistent
with another detailed study of superinfection in the setting of
immune control achieved by structured treatment interruption
therapy in early infection (2). This phenomenon is also remi-
niscent of the increased viremia that has been observed with
escape occurring during natural infection (15, 32) and reinfu-
sion of an ex vivo expanded CTL clone (24) and associated
with SIV vaccine failure in macaques (6). The ability of CTL to
recognize the challenging viral sequences thus appears to be a
crucial determinant of immune control.
Superinfection and loss of immune control in this subject,
despite apparently effective CTL responses to the initial strain,
may have serious implications for vaccine design. The deter-
minants of an effective CTL response against HIV-1 remain
unknown, and attempts to correlate the magnitude or breadth
of the response (8) to control of viremia generally have been
disappointing (1). Our data, in agreement with those of Altfeld
et al. (2), indicate that protective CTL targeting against HIV-1
may vary not only by subtype of virus but even by individual
strains. Given the great variability of HIV-1, this phenomenon
may pose a significant obstacle to generating protective immu-
nity with a fixed vaccine sequence.
FIG. 6. Dynamics of early and subsequent CTL responses for subject 2030. The sum of CTL frequencies for responses detected upon initial
testing (month 0) are plotted over time, in comparison to the sum of frequencies of CTL responses detected only after initial testing. PBMC,
peripheral blood mononuclear cells.
TABLE 1. CTL responses over timea
Peptide (ARRRR no.) Location
SFC count on month indicated
0 3 5 9
LKETINEEAAEWDRV (5035) Gag 201–215 (p24) 0 143 0 0
INEEAAEWDRVHPVH (5036) Gag 205–219 (p24) 321 253 138 0
AAEWDRVHPVHAGPI (5037) Gag 209–223 (p24) 899 341 328 0
DRVHPVHAGPIAPGQ (5038) Gag 213–227 (p24) 45 0 0 0
GPIAPGQMREPRGSD (5040) Gag 221–235 (p24) 42 0 0 0
PGQMREPRGSDIAGT (5041) Gag 225–239 (p24) 238 0 0 0
EPIDKELYPLTSLRS (5104) Gag 477–491 (p6) 0 270 208 0
KIATESIVIWGKTPK (5593) Pol 529–543 (RT) 0 0 65 0
WPTVRERMRRAEPAA (5142) Nef 13–27 0 0 0 60
EVGFPVRPQVPLRPM (5155) Nef 65–79 0 255 0 448
PGPGIRYPLTFGWCF (5171) Nef 129–143 231 927 463 401
IRYPLTFGWCFKLVP (5172) Nef 133–147 704 1,185 559 0
KCCFHCQVCFTTKGL (5120) Tat 29–43 0 148 0 0
DEELLKTVRLIKFLY (5993) Rev 9–23 0 0 0 764
LKTVRLIKFLYQSNP (5994) Rev 13–27 0 0 0 789
YWGLHTGERDWHLGQ (6035) Vif 69–83 704 215 268 43
HTGERDWHLGQGVSI (6036) Vif 73–87 831 361 376 62
a CTL responses identified by ELISPOT screening against overlapping peptides (obtained from the NIH ARRRR) are shown. The locations of the peptides (in
relationship to the HXB2 sequence) are given. Values are SFC per 106 CD8 T lymphocytes (means of results of duplicate experiments).
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